Intelligence Β· Patent portfolio
Regeneron Ireland Designated Patents
Full USPTO pharma patent portfolio for Regeneron Ireland Designated β grant dates, expiration, and drug cross-links.
- Patents
- 8,292
- Expiring β€24m
- 426
Quick answer
Regeneron Ireland Designated has 8,292 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 426 expire within 24 months β use filters for patent-cliff planning.
-
US 7135611
Compositions and methods for characterizing and regulating Wnt pathways
granted -
US 7135177
Immunoliposomes that optimize internalization into target cells
granted -
US 7132403
Antihelminthic anthraquinones and method of use thereof
granted -
US 7132271
Methods for enhancing the production of viral vaccines in cell culture
granted -
US 7132454
HEXIM1 as a suppressor of HIV replication and cardiac hypertrophy
granted -
US 7132122
Direct micro-patterning of lipid bilayers using UV light and selected uses thereof
granted -
US 7129039
Unique dendritic cell-associated C-type lectins, dectin-1 and dectin-2; compositions and uses thereof
granted -
US 7128904
Material containing metal ion ligand complex producing nitric oxide in contact with blood
granted -
US 7128895
Use of bile acid derivatives conjugated with metal ion chelated complexes for the diagnostic assessment of microvascular permeability
granted -
US 7125965
MRI probes of membrane potential
granted -
US 7125857
Modulators of DNA cytosine-5 methyltransferase and methods for use thereof
granted -
US 7125541
Combined methods for tumor vasculature targeting and tumor treatment with radiotherapy
granted -
US 7125866
Therapeutic applications of pro-apoptotic benzodiazepines
granted -
US 7125969
ETS-related gene overexpressed in human breast and epithelial cancers
granted -
US 7122714
Mouse models of human prostate cancer
granted -
US 7122579
Eye treatments using synthetic thyroid hormone compositions
granted -
US 7122200
Vitro engineered, regenerated urinary tract tissue compositions and methods for producing same
granted -
US 7122572
Calixpyrroles
granted -
US 7119105
Methods for treating neurodegenerative disorders using aspartyl protease inhibitors
granted -
US 7118865
Methods for diagnosing severe systemic lupus erythematosus
granted -
US 7119064
Use of colostrinin, constituent peptides thereof, and analogs thereof as modulators of intracellular signaling molecules
granted -
US 7119223
Interleukin-1 and tumor necrosis factor-Ξ± modulators, synthesis of said modulators and their enantiomers and methods of using said modulators
granted -
US 7115405
Hyaluronan synthase gene and uses thereof
granted -
US 7115560
Methods for modulating gastric secretion using prokineticin receptor antagonists
granted -
US 7115360
Isolation and use of solid tumor stem cells
granted -
US 7115577
Colorectal neoplasia prophylaxis
granted -
US 7115260
Interleukin-1Ξ² converting enzyme like apoptotic protease-6
granted -
US 7115582
HoxD3 and HoxA3 compositions and methods for improved wound healing
granted -
US 7112566
Systemic administration of Hypocretin-1
granted -
US 7112317
Combined methods and compositions for tumor vasculature targeting and tumor treatment
granted -
US 7112442
Peptides for gene delivery
granted -
US 7112338
Cationic liposome delivery of taxanes to angiogenic blood vessels
granted -
US 7109011
Hyaluronan synthase gene and uses thereof
granted -
US 7109188
Methods and compositions for treating atheroma, tumors and other neoplastic tissue
granted -
US 7109179
Methods and compositions comprising DNA damaging agents and p53
granted -
US 7108986
Glypican-1 in human breast cancer
granted -
US 7108975
Atlastin
granted -
US 7105561
Use of etodolac for the treatment of prostate cancer
granted -
US 7105695
Synthesis of combretastatin A-2 prodrugs
granted -
US 7105183
Chlorite in the treatment of neurodegenerative disease
granted -
US 7105560
Use of etodolac in the treatment of multiple myeloma
granted -
US 7105330
Human plasma hyaluronidase
granted -
US 7105641
MCP-1 receptor antibodies
granted -
US 7105156
Method of using an adenoviral vector encoding a retinoblastoma protein to treat hyperproliferating cells
granted -
US 7105171
Porin B (PorB) as a therapeutic target for prevention and treatment of infection by Chlamydia
granted -
US 7101852
Composition and method for treatment and prevention of restenosis
granted -
US 7101846
Methods and compositions for optimization of oxygen transport by cell-free systems
granted -
US 7101557
Combined tissue factor methods for coagulation and tumor treatment
granted
Frequently asked questions
How many patents does Regeneron Ireland Designated have?
8,292 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Regeneron Ireland Designated patents expire?
426 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.
Where does this data come from?
USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.
Data attribution: Data sources Β· Patent directory